In order to enhance the lethality of cytotoxic T cells against cancer cells, researchers developed a competitive peptide that specifically inhibits PD-L1, surpassing the commonly used universal palmitoylation inhibitor 2-BP in terms of specificity. This evidence concerns the gene CD274 and cancer.